Treats metastatic non-small cell lung cancer (NSCLC). ANDA 91059, held by Teva Pharmaceuticals USA. Erlotinib Hydrochloride.
As of Nov 22, 2026, ANDA 91059 (Erlotinib Hydrochloride), held by Teva Pharmaceuticals USA, was first approved by FDA on Nov 9, 2020, with 1 approved supplement and 0 published complete response letters.
Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
| Nov 9, 2020 | Original application | Approved | None posted |
| Aug 28, 2015 | Original application | Approved | None posted |
| Erlotinib HydrochlorideEQ 25MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
| Erlotinib HydrochlorideEQ 100MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
| Erlotinib HydrochlorideEQ 150MG BASE · tablet;oral | Erlotinib Hydrochloride | Rx |
| Nov 9, 2020 | Original application | Approved | None posted |
| Oct 28, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 28, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters